PT  - JOURNAL ARTICLE
AU  - Thomsen, Mette
AU  - Dahl, Morten
AU  - Lange, Peter
AU  - Vestbo, Jørgen
AU  - Nordestgaard, Børge
TI  - Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P455
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P455.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P455.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - BackgroundPatients with chronic obstructive pulmonary disease (COPD) have evidence of systemic inflammation that may be implicated in the development of comorbidities. We tested the hypothesis that elevated levels of three inflammatory biomarkers are associated with increased risk of comorbidities in COPD.MethodsWe measured baseline C-reactive protein (CRP), fibrinogen, and leukocyte count in 10,052 COPD patients from two large population studies. During a median 5-years follow-up we recorded hospital admissions due to ischemic heart disease, myocardial infarction, heart failure, type II diabetes, lung cancer, pneumonia, pulmonary embolism, hip fracture, and depression as endpoints.ResultsMultifactorially adjusted risk of ischemic heart disease was increased by a factor of 2.19 (95% confidence interval 1.48 to 3.23) in individuals with three biomarkers elevated (CRP above 3 mg per liter, fibrinogen above 14 μmol per liter, and leukocyte count above 9 x109 per liter) versus individuals with all three biomarkers at or below these limits. Corresponding hazard ratios were 2.32 (1.34 to 4.04) for myocardial infarction, 2.63 (1.71 to 4.04) for heart failure, 3.54 (2.03 to 6.19) for diabetes, 4.00 (2.12 to 7.54) for lung cancer, and 2.71 (2.03 to 3.63) for pneumonia. There were no consistent differences in risk of pulmonary embolism, hip fracture, or depression as a function of these three biomarkers.ConclusionsSimultaneously elevated levels of CRP, fibrinogen, and leukocyte count are associated with a 2 to 4-fold increased risk of major comorbidities in COPD. These findings may enable clinicians to conduct stratified management of comorbidities in COPD patients.